Zhitong Finance App News, Yisheng Biotechnology (01061) issued an announcement. The Group expects revenue and profit for the six months ending June 30, 2026 (mid-term period 2026) to be reduced by about 10% and 30% respectively compared to the Group's revenue of HK$887 million and profit of HK$163 million for the same period in 2025, mainly due to the increase in value-added tax borne by the Group after China implemented the new value tax law.

Despite this situation, the Group maintained a steady cash flow and financial position to meet its business needs. As at 30 June 2026, the Group's cash and cash equivalents were approximately HK$807 million.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.